Aspen Secures Distribution Rights In South Africa From Amgen
Aspen Secures Distribution Rights In South Africa From Amgen. Aspen is pleased to announce that it has concluded an agreement with Amgen, in terms of which Aspen will exclusively market, distribute, use, and sell Amgen’s products in South Africa for an initial term of 5 years, which will be renewed. Amgen is a biotechnology pioneer whose medicines reach millions of seriously ill patients around the world. Amgen’s products include Aranesp, Amgevita, Prolia, Repatha, NPlate, Vectibix and Blincyto.
Amgen will continue to manufacture and supply its products to Aspen for the duration of the contract. The Transaction includes future pipeline products and an opportunity for expansion of the Territory into the rest of Sub-Saharan Africa. The transaction will complete by 01 July 2023.
The transaction forms part of Aspen’s strategy to be a partner of choice to leading global pharmaceutical and biotechnology companies for niche products in emerging markets. Amgen focuses on areas of high unmet medical need and has a robust pipeline including biosimilars that will be registered and/or submitted for registration in the near future. At present, Aspen is not represented in these therapeutic areas with high growth potential.
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. A biotechnology pioneer since 1980, Amgen has grown to be one of the world’s leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.
